{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'surveillance/watchful waiting without intent to treat, or carcinoma in situ of any', 'type (if complete resection was performed) are allowed.', 'Waivers to the COE exclusion criteria will NOT be allowed.', '12.10.4 Schedule and Assessments', 'Arm B subjects meeting criteria as indicated in [Section 12.10.3] will sign informed', 'consent prior to COE Day 1 dosing. The COE subjects will follow the COE Schematic', 'and COE Schedule of Assessments [Table 11].', '14 Sep 2020', 'Astellas', 'Page 131 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Figure 2', 'Crossover Extension Schema', 'Treatment: Days 1, 8 & 15 of', 'ARM B: Docetaxel,', 'COE: Enfortumab Vedotin', 'each 28-day cycle until', 'Follow-up for PFS2/os', 'Paclitaxel or Vinflunine', 'discontinuation criteria met', 'COE: crossover extension; OS: overall survival; PFS2: progression free survival on subsequent therapy', 'Table 11', 'Schedule of Assessments for Crossover Extension', 'Long Term PFS2', 'End of', 'Treatment', 'Survival', 'Visit', 'Every Cycle', 'Treatment\u00b9', 'Follow-up2', 'Follow-up', 'Follow-up', 'Date of last', 'Day 8', 'Day 15', 'Every', 'Date of Last', 'Day 1', 'Dose + 30', 'Dose', 'Every 3 months', 'Every 3 months', 'Base Date', '56 Days', 'days', 'Visit Window', '3 days', '3 day', '3 days', '7 days', '+ 7 days', '+ 7 days', '7 days', '7 days', 'Informed Consent', 'X3,4', 'Confirmation of', 'X3,4', 'Eligibility for COE', 'Brain Scan5', 'X3,5', 'X5', 'Bone Scan6', 'X6', 'X6', 'Serum/Urine', 'X', 'X', 'X', 'X7', 'X7', 'Pregnancy Test7', 'Physical Examination8', 'X', 'X', 'Weight8', 'X', 'X', 'X', 'X', 'Vital Signs8', 'X', 'X', 'X', 'X', 'X', 'Biochemistry9', 'X', 'X', 'X', 'X', 'X', 'Hemoglobin A1C10', 'X', 'X', 'Hematology11', 'X', 'X', 'X', 'X', 'X', 'ECOG PS', 'X', 'X', 'X', '12-lead ECG12', 'X3,12', 'X12', '14 Sep 2020', 'Astellas', 'Page 132 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Ophthalmology', 'X', 'X', 'Assessment13', 'COE Enrollment via', 'X4', 'IRT', 'EV Administration', 'X', 'X', 'X', 'Image Assessment14', 'X', 'X14', 'Concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'Medication', 'Adverse Events', 'X', 'X', 'X', 'X', 'X', 'X', 'QOL15', 'X', 'X', 'X', 'HRU16', 'X16', 'X', 'X', 'ATA19', 'X', 'X', 'X', 'Subsequent Therapy', 'X', 'X', 'Assessment17', 'Overall Survival18', 'X', 'X', 'X', 'AE: adverse event; ALT: alanine transaminase; AST: aspartate transaminase; ATA: antitherapeutic antibody; C: cycle; COE: crossover', 'extension;', 'CR: complete response; CT: computed tomography; D: day; ECG: electrocardiogram; ECOG PS: Eastern Cooperative Oncology Group', 'Performance Status; EORTC-QLQ-C30: European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire; EOT:', 'end of treatment; EQ-5D-5L: EuroQOL 5-Dimension 5-Level Questionnaire; EV: enfortumab vedotin; HRU: health resource', 'utilization;', 'MRI:', 'magnetic resonance imaging; NA: Not Applicable; PD: progressive disease; PFS1: progression free survival on study therapy; PFS2: progression free', 'survival on subsequent therapy; PGx: Pharmacogenetic analyses; PR: partial response; QOL: quality of life; RECIST: Response Evaluation Criteria', 'in Solid Tumors', '1. EOT visit will occur within 7 days after the last dose or when the decision is made by the investigator to discontinue subject from treatment.', '2. Follow up assessments should be completed prior to the initiation of the next therapy.', '3. May be completed within 28 days prior to COE C1D1 visit.', '4. COE Cycle 1 only.', '5. Only if clinically indicated at time of COE eligibility assessment. Repeat as clinically indicated or per standard of care throughout the study.', '6. All subjects will have a bone scan (scintigraphy) within 28 days prior to COE C1D1 dosing. Subjects with positive bone scans at time of COE', 'eligibility assessment will have a bone scan performed every 56 days ( 7 days) throughout the study or more frequently if clinically', 'indicated. Subjects should have a follow-up bone scan performed if clinically indicated regardless of status at time of COE', 'eligibility', 'assessment.', '7. For all female subjects of child bearing potential only, a urine or serum pregnancy test will be performed within -7 days of COE C1D1 visit.', 'A urine or serum pregnancy test will be performed at COE Day 1 prior to dosing, on day 1 of each cycle prior to EV administration,', 'at', 'EOT', 'and Follow-up visits. After EOT, a monthly ( 7 days) pregnancy test will be maintained until 6 months after the last dose of study treatment.', '8. Full Physical examination, weight, ECOG PS and vital signs (pulse, temperature and blood pressure) will be performed at', 'COE', 'C1D1', 'prior', 'to dosing. The physical examination will also be performed on day 1 of each cycle and EOT visit. For subsequent and EOT visits, physical', '14 Sep 2020', 'Astellas', 'Page 133 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}